# **HEALEY ALS Platform Trial**

#### Weekly Q&A - Nov 18, 2021





# **Healey Center**

Sean M. Healey & AMG Center for ALS at Mass General



















uch
























### **Guest Speaker**

#### James Berry, MD, MPH Massachusetts General Hospital Regimen co-Lead (Regimen C)



#### Perpetual Adaptive Trial Shared Placebo; Randomization Ratio 3:1 Open Label Extension (OLE) offered





#### **Primary Endpoint**


Change in disease severity - ALS Functional Rating Scale-Revised (ALSFRS-R)

#### **Secondary Endpoints**

- 1. Change in respiratory function slow vital capacity (SVC)
- 2. Change in muscle strength hand held dynamometry (HHD)
- 3. Survival
- 4. Treatment-specific biomarkers as applicable

#### **Exploratory Endpoints**

#### **Safety Endpoints**



## **Regimens A, B and C completed enrollment!**

162 individuals were randomized within Regimen A
167 individuals were randomized within Regimen B
161 individuals were randomized within Regimen C
146 individuals were randomized within Regimen D
282 have entered the Open Label Extension (OLE)

Home - News - Press Release

PRESS RELEASE · 5 MINUTE READ · NOV | 15 | 2021

The HEALEY ALS Platform Trial completes enrollment for first three investigational treatments

Marcela Quintanilla-Dieck · 617-726-0954 · mquintanilladieck@mgh.harvard.edu

This is a critical milestone, guiding the timeline for trial completion and result reporting, ultimately putting us on the path forward towards finding treatments for people with ALS.

Merit Cudkowicz, MD Director, Sean M. Healey & AMG Center for ALS at MGH



Type

Topics

Research

Press Release

Centers and Departments

Healey Center for ALS, Neurology



This breakthrough trial would not be possible without your partnership

as of 11/18/21 6

# Plans for Expansion: New Sites Coming Soon



- Matrium Health
- Cleveland Clinic
- George Washington University
- ☑ University of California, San Francisco
- **Yale University**
- Mana University
- Stony Brook University
- C Georgetown University
- **W** University of Arkansas
- C University of Pittsburgh
- C University of Southern California

- **W** University of Utah
- Magusta University
- Muniversity of Cincinnati
- Virginia Commonwealth University
- Swedish Medical Center
- 🗹 Las Vegas Clinic
- 🗹 Kaiser, Los Angeles
- Lehigh Valley Health Network
- St. Alphonsus Regional Medical Center
- Mackensack University
- Essentia Health

Note: Only those sites highlighted in blue are active at this time. Additional sites will be activated on a rolling basis.

## Patient Navigator



# Catherine Small

#### **Allison Bulat**

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Eligibility criteria:



**Enrolling sites:** 





# **Finding Other Clinical Trial Opportunities**

clinicaltrials.gov



**CDC National ALS Registry** 

**NEALS Website** 

ALS Signal from I AM ALS



ALS Clinical Trial Liaison contact info (855) 437- 4823 alstrials@neals.org

## Send us webinar ideas!

- Biostatistics
- Get to know our sites

#### **Upcoming Guest Speakers:**





- Nov 25<sup>th</sup>- No Webinar, Happy Thanksgiving!
- Dec 2<sup>nd</sup>- Neil Thakur, PhD (The ALS Association)
- Dec 9th- Nicholas Olney, MD (Providence ALS Clinic, OR)
- Dec 16th- Lori Chibnik, PhD, MPH (Biostatistics)
- Dec 23<sup>rd</sup>- No Webinar, Happy Holidays!
- **Dec 30<sup>th</sup>- No Webinar, Happy Holidays!**

### Join the ALS Link!

- Sign up to receive news and updates via email from the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital
- Get the latest information about ALS clinical trials, clinical care, and webinar opportunities

Home - Neurology - ALS



At the Healey Center for ALS, we are on a quest to discover life-saving therapies for approximately 500,000 people worldwide who are affected by amyotrophic lateral sclerosis (ALS).



